Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

Sponsor
University of Jena
Study ID
NCT04338958
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ruxolitinib — DRUG
    2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days with clinical and/or radiographic response assessment

Study Details

RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of Covid-19 patients with defined hyperinflammation.

Key Dates

Start date
Apr 22, 2020
Status verified
Aug 2021
Primary completion
Jul 15, 2021
Completion
Jul 15, 2021

Study Design

Enrollment
193 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ruxolitinib
    2 x 10mg Ruxolitinib with defined response adapted dose escalation up to 2 x 20mg for a duration of 7 days

Primary Outcome Measure

overall response rate in reversal of hyperinflammation [ Time Frame: day 7 after start of therapy ]

Related Studies